Forte Biosciences, Inc. (FBRX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Pluri, Inc.

OncoCyte Corp.

Equillium, Inc.

Pieris Pharmaceuticals, Inc.

Forte Biosciences, Inc.

Coeptis Therapeutics Holdings, Inc.

Enlivex Therapeutics Ltd.

Cyclo Therapeutics, Inc.

Seelos Therapeutics, Inc.

Elevation Oncology, Inc.

Rain Oncology, Inc.

Why is Forte Biosciences, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Forte Biosciences, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Forte Biosciences, Inc.

-18.79%

0.36

126.51%

S&P 500

12.66%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-0.40%

EBIT Growth (5y)

-2.39%

EBIT to Interest (avg)

-26.83

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.19

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

84.12%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.94

EV to EBIT

-0.64

EV to EBITDA

-0.64

EV to Capital Employed

-3.86

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-113.76%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

NET PROFIT(HY)

Higher at USD -26.91 MM

ROCE(HY)

Highest at -73.46%

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

CASH AND EQV(HY)

Highest at USD 152 MM

EPS(Q)

Highest at USD -0.96

-7What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -38.56 MM

NET PROFIT(HY)

At USD -26.91 MM has Grown at -34.99%

Here's what is working for Forte Biosciences, Inc.

Net Profit

Higher at USD -26.91 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

EPS

Highest at USD -0.96

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Cash and Eqv

Highest at USD 152 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Forte Biosciences, Inc.

Operating Cash Flow

Lowest at USD -38.56 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Net Profit

At USD -26.91 MM has Grown at -34.99%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)